Related Experiment Video

Updated: May 21, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Cardio-ankle vascular index in heterozygous familial hypercholesterolemia

Vladimir Soska1, Petr Dobsak, Ladislav Dusek

  • 12nd Clinic of Internal Medicine, Masaryk University of Brno, Czech Republic. vladimir.soska@fnusa.cz

Journal of Atherosclerosis and Thrombosis
|June 5, 2012
PubMed

Insights

Cardio-ankle vascular index (CAVI) did not significantly differ between familial hypercholesterolemia (FH) patients and healthy controls after adjusting for age, sex, and BMI. This suggests CAVI may not be a sensitive marker for early atherosclerosis in FH.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Genetics

Background:

  • Arterial stiffness and atherosclerosis are key indicators of cardiovascular risk.
  • Cardio-ankle vascular index (CAVI) is a novel, non-invasive measure of arterial stiffness.
  • Familial hypercholesterolemia (FH) is an inherited condition leading to high cholesterol and premature atherosclerosis.

Purpose of the Study:

  • To compare CAVI values in patients with heterozygous familial hypercholesterolemia (FH) against healthy controls.
  • To investigate the utility of CAVI as a marker for subclinical vascular changes in FH.

Main Methods:

  • A cross-sectional study involving 82 FH patients and 359 healthy controls.
  • CAVI was measured using the VaSera® 1500 system.
  • Statistical analysis included age, sex, and BMI adjustments.

Main Results:

  • Unadjusted CAVI was significantly higher in FH patients (8.0±1.4) compared to controls (7.5±1.3), p=0.002.
  • However, age, sex, and BMI adjusted CAVI showed no significant difference between groups (p=0.061).

Conclusions:

  • This study found no significant difference in adjusted CAVI between heterozygous FH patients and healthy controls.
  • CAVI may not be a sensitive indicator of early arterial stiffness or atherosclerosis in FH when adjusted for key demographic factors.
Abstract

More Related Videos

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiovascular System Abnormal Findings I: Inspection and Palpation01:29

Cardiovascular System Abnormal Findings I: Inspection and Palpation

In a cardiovascular examination, inspection and palpation are crucial for identifying abnormalities.
Abnormal findings observed during an inspection
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...